T 1677/11 ((-)-Omeprazole Na/ASTRAZENECA) of 27.11.2012

European Case Law Identifier: ECLI:EP:BA:2012:T167711.20121127
Date of decision: 27 November 2012
Case number: T 1677/11
Application number: 00108479.7
IPC class: C07D 401/12
A61K 31/44
A61P 1/04
Language of proceedings: EN
Distribution: C
Download and more information:
Decision text in EN (PDF, 421.070K)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: The sodium salt of the (-)-enantiomer of omeprazole
Applicant name: AstraZeneca AB
Opponent name: Farmaprojects, S.A.
Wittkopp, Alexander
Teva Pharmaceutical Industries Ltd.
Actavis Group hf.
LEK Pharmaceuticals d.d.
Hörnchen, Ulrich, Dr.
Board: 3.3.01
Headnote: -
Relevant legal provisions:
European Patent Convention Art 24(3)
European Patent Convention Art 54
European Patent Convention Art 56
European Patent Convention Art 87
European Patent Convention Art 100(b)
European Patent Convention Art 100(c)
European Patent Convention R 115(2)
Rules of procedure of the Boards of Appeal Art 15(3)
BDS Art 007
Keywords: Admissibility of partiality objections (no)
Main request, allowable
Added matter (no)
Sufficiency (yes), starting material retrievable from Chemical Abstracts
Novelty (yes), specific salt
Inventive step (yes), post-published evidence (yes), unexpected advantage
Catchwords:

-

Cited decisions:
G 0005/91
T 0206/83
T 0296/87
T 0292/92
T 0990/96
T 1028/96
T 0967/97
T 0609/02
T 0401/04
T 0591/04
T 1329/04
T 0021/08
T 1760/11
Citing decisions:
T 2059/13
T 0488/16

23 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

EPC Implementing Rules

Offical Journal of the EPO

Case Law Book: III Amendments

Case Law of the Enlarged Board

General Case Law